---
title: "Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295708161.md"
description: "On August 12, 2026, in South San Francisco, Allogene Therapeutics, Inc. (Nasdaq: ALLO), a leading clinical-stage biotechnology firm specializing in allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, shared corporate news and disclosed financial outcomes for the quarter concluding on June 30, 2026."
datetime: "2026-08-12T20:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295708161.md)
  - [en](https://longbridge.com/en/news/295708161.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295708161.md)
generator: "portal-rs"
---

# Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

On August 12, 2026, in South San Francisco, Allogene Therapeutics, Inc. (Nasdaq: ALLO), a leading clinical-stage biotechnology firm specializing in allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, shared corporate news and disclosed financial outcomes for the quarter concluding on June 30, 2026.

### Related Stocks

- [ALLO.US](https://longbridge.com/en/quote/ALLO.US.md)

## Related News & Research

- [Allogene Therapeutics Announces Retirement of Chief Financial Officer](https://longbridge.com/en/news/297799207.md)
- [701,901 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Man Group plc](https://longbridge.com/en/news/297885797.md)
- [BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?](https://longbridge.com/en/news/297786944.md)
- [ALLO: Allogeneic CAR T platform shows strong efficacy, safety, and broad market potential across key indications](https://longbridge.com/en/news/295718267.md)
- [Allogene Therapeutics to present at Citi Biopharma Back to School Conference](https://longbridge.com/en/news/297517604.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**